Tech Company Financing Transactions

Allena Pharmaceuticals Funding Round

Partner Fund Management, Fidelity Management & Research Company and Frazier Healthcare Partners participated in a $53 million Series C funding round for Allena Pharmaceuticals. The round was announced on 12/9/2015.

Transaction Overview

Company Name
Allena Pharmaceuticals
Announced On
12/9/2015
Transaction Type
Venture Equity
Amount
$53,000,000
Round
Series C
Investors

Partner Fund Management (Lead Investor)

Fidelity Management & Research Company

Frazier Healthcare Partners (James Topper)

HBM Healthcare Investments (Axel Bolte)

Pharmstandard

Wellington Management Company

Proceeds Purpose
Allena intends to use the proceeds from the financing to advance its lead product candidate, ALLN-177 for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones, into Phase 3 clinical trials. The proceeds will also be used to explore additional indications for ALLN-177, including oxalate nephropathy and primary hyperoxaluria, and to develop new product candidates utilizing Allena's non-systemic oral protein therapeutic platform.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Executive Park Dr. 202
Newton, MA 02462
USA
Phone
617-467-4577
Website
www.allenapharma.com
Email Address
[email protected]
Overview
Allena Pharmaceuticals (Nasdaq: ALNA) develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.
Profile
Allena Pharmaceuticals LinkedIn Company Profile
Social Media
Allena Pharmaceuticals Company Twitter Account
Company News
Allena Pharmaceuticals News
Facebook
Allena Pharmaceuticals on Facebook
YouTube
Allena Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Louis Brenner
  Louis Brenner LinkedIn Profile  Louis Brenner Twitter Account  Louis Brenner News  Louis Brenner on Facebook
Chief Financial Officer
Edward Wholihan
  Edward Wholihan LinkedIn Profile  Edward Wholihan Twitter Account  Edward Wholihan News  Edward Wholihan on Facebook
Chief Medical Officer
Annamaria Kausz
  Annamaria Kausz LinkedIn Profile  Annamaria Kausz Twitter Account  Annamaria Kausz News  Annamaria Kausz on Facebook
Vice President
Geoffrey Swire
  Geoffrey Swire LinkedIn Profile  Geoffrey Swire Twitter Account  Geoffrey Swire News  Geoffrey Swire on Facebook
VP - Operations
Hugh Wight
  Hugh Wight LinkedIn Profile  Hugh Wight Twitter Account  Hugh Wight News  Hugh Wight on Facebook
VP - Regulatory Affairs
Stephen Yu
  Stephen Yu LinkedIn Profile  Stephen Yu Twitter Account  Stephen Yu News  Stephen Yu on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/9/2015: Slash venture capital transaction
Next: 12/9/2015: Ematic Solutions venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.